To enhance immunity induced by DNA vaccination against human immunodeficiency virus type 1 (HIV-1), we evaluated the efficacy of monophosphoryl lipid A (MPL), an adjuvant of bacterial origin. BALB/c mice were intramuscularly injected with immunogenic DNA, encoding the env and rev genes of the HIV-1 IIIB strain, formulated with MPL dissolved in different vehicles (MPL in stable emulsion and MPL in aqueous formulation). The sera from mice immunized with the two preparations of MPL revealed 2 6 to 2 9 times higher HIV-1-specific immunoglobulin G (IgG) titers than the sera from mice immunized without MPL. In virus neutralization tests for HIV-1 IIIB by p24 assay and antifusion assay of infected MOLT-4 cells, MPL tends to elicit antibody more protective than antibody elicited without adjuvant. MPL also elicited stronger delayedtype hypersensitivity and cytotoxic-T-lymphocyte activity against HIV-1 IIIB compared to DNA alone. HIV-1-specific IgG subclass analysis showed that MPL tends to facilitate IgG2a production, suggesting enhancement of a predominant T-helper-type-1 response, and this enhancement may help to facilitate protective-antibody induction. Furthermore, a chloramphenicol acetyltransferase (CAT) assay was employed to determine whether MPL affected the gene expression process. Interestingly, both MPL preparations reduced CAT activity in the muscle injected with CAT expression vector but increased anti-CAT antibody production. These results indicate that MPL acts as an effective adjuvant for immunogenic DNA injection despite reduced expression of encoding protein in muscle. We conclude that MPL has a strong adjuvant effect on DNA vaccination against HIV-1.
Human immunodeficiency virus type 1 (HIV-1) infection has shown pandemic extension. Although the development of effective vaccines to combat HIV infections is urgently required, studies on AIDS vaccines have not yet achieved satisfactory results. The use of plasmid DNA encoding microbial antigen to elicit protective immunity against some pathogenic viruses has been reported to be highly effective in mice (31, 39) and is referred to as DNA vaccination or genetic immunization. Also in the field of AIDS vaccine study, we and others have reported successful DNA vaccination inducing HIV-1-specific immunity in laboratory models (16, 21) . This novel approach is expected to have some advantages over approaches involving use of the classical protein-based vaccines. Three unique features of DNA vaccination can be roughly outlined. Firstly, the intracellular synthesis of an encoded antigenic protein results in presentation by class I major histocompatibility complex surface molecules (11) . Thus, DNA vaccines should induce cytotoxic-T-lymphocyte (CTL) activity, as does the live attenuated vaccine. Emphasis is placed on the importance of the induction of CTL activity and T-helpertype-1 (Th1)-derived cell-mediated immunity (CMI) among the protective mechanisms against HIV and simian immunodeficiency virus infection (6, 10, 19, 35) . Secondly, the transferred gene can be expressed over a sustained period of time, allowing the continuous presence of low levels of antigen (8) . This feature may preclude the requirement for booster immunization. The third unique feature is that, since DNA is amenable to genetic manipulation, it is possible to design an immunogenic DNA that encodes multiple antigenic proteins (11) .
The fact that the same antigen with different adjuvants induces different responses is well known also in the field of AIDS vaccine study (13, 24) . Recently developed adjuvants have been shown to elicit CTL activities or Th1-derived CMI (20, 40) as well as antibodies (Abs) to peptide antigens. Thus, the use of these adjuvants in DNA vaccine should be effective for enhancing the induced immune responses. One promising adjuvant is monophosphoryl lipid A (MPL), a detoxified form of lipid A derived from the lipopolysaccharide of Salmonella minnesota R595 (32) . Early studies (9, 26, 28) have shown that the adjuvant activity of MPL relates to its potential to activate macrophages and its ability to induce interferon gamma (IFN-␥) and interleukin 2 (IL-2), known to be essential for the induction of Th1-derived CMI (19) . Moreover, stimulation of bone marrow-derived antigen-presenting cells (APCs), such as macrophages and dendritic cells, has been suggested to be important for enhancing the immune response induced by DNA vaccination (4, 38) . Therefore, MPL is capable of acting as an effective adjuvant in DNA vaccination through activation of macrophages as professional APCs and elicitation of Th1-type cytokines. We have developed a DNA vaccine (21) which induces an HIV-1-specific immune response; however, adjuvants that enhance immunogenicity have not been incorporated into the vaccine formulation. The present study was designed to evaluate whether MPL exhibits immunomodulatory effects on the DNA vaccine against HIV-1. We demonstrated that this adjuvant elicits humoral and cell-mediated ) labeled with [
51 Cr]sodium chromate. After being cultured for 5 days, the bulk splenocytes used as effector cells were cocultivated with the target cells at effector-to-target cell (E/T) ratios that ranged from 5:1 to 80:1. Target cell lysis was measured by gamma-ray counting of 200 l of cell-free supernatant to determine the amount of 51 Cr released. (23) . Two weeks after immunization, 10 g of V3 peptide was injected into the rear footpads of each mouse. Since a V3 peptide sequence is reported to occur in both CTL (15) and helper (29) epitopes, we used the same peptide in the CTL and DTH assays. The extent of footpad swelling was measured 24 h after peptide injection with a microdial meter (Ozaki Seisakusho, Tokyo, Japan) as the difference in footpad thickness between the pre-and postinjection measurements in units of 10 Ϫ2 mm. Control mice were injected with the same dose of sperm whale myoglobin peptide, ALVEADVA.
Virus neutralization test for HIV-1 IIIB . The neutralizing activities of the serum samples collected 14 and 28 days after immunization were analyzed by the virus growth inhibition test by using a p24 protein assay as described elsewhere (2) . A 2% solution of serum samples from each immunized or control mouse was added to a medium containing HIV-1 IIIB (provided by the NIH AIDS Research and Reference Reagent Program) and incubated for 1 h. Uninfected CEM cells were added to the medium containing the virus and were then washed and cultured for 5 days. The concentration of p24 protein in the cell-free supernatants was measured by an HIV-1-specific enzyme immunoassay (Abbott, North Chicago, Ill.) according to the manufacturer's instructions.
Antifusion assay. An antifusion assay was carried out as previously reported (25), using day 28 antisera. CEM cells were infected with HIV-1 IIIB and then cultured for 5 days. Stably infected CEM cells were first incubated for 2 h at several concentrations in serum samples. Uninfected MOLT-4 cells were then added to this culture system (infected-to-uninfected cell ratio of 1:10). After the plates were incubated for 24 h at 37°C, fused giant cells were counted. The antifusion activities were expressed as percentages of reduction in the levels of syncytium formation by the immune sera compared with those obtained with the serum-free culture medium.
Reporter gene expression assay (CAT assay). BALB/c mice were injected with 100 g of pCMV-CAT diluted in 100 l of normal saline or saline containing 50 l of either MPL-SE or MPL-AF in the bicep femoris muscles. One week after transfection, each mouse was sacrificed by cervical dislocation and both bicep femoris muscles were dissected and transferred into 500 l of muscle lysis buffer (10 mM Tris-HCl [pH 7.8], 2 mM MgCl 2 , 0.5% Tween 20) . The muscles were then immediately frozen with liquid nitrogen and thawed in a water bath at 37°C and subsequently homogenized with a homogenizer (Ultra Disperser Model LK-21; Yamato, Tokyo, Japan). Next, the homogenized muscle tissue was subjected to three freeze-thaw cycles and heated at 70°C for 20 min to inactivate endogenous acetyltransferase, and saved supernatant was subjected to the CAT assay. CAT activity was determined with an assay kit (Quant-T-CAT; Amersham, Buckinghamshire, United Kingdom), essentially according to the manufacturer's instructions with the exception that the samples were incubated at 40°C for 1 h.
Histopathological examination. Ten micrograms of pCMV-CAT formulated with 50 l of MPL-SE dissolved in PBS was injected into the bicep femoris muscles of BALB/c mice. Three days after injection, muscles were resected and fixed with 10% buffered formalin and were embedded in paraffin. Sections were then stained with hematoxylin and eosin for light microscopic observation. Negative control mice were injected with the same amount of pCMV-CAT alone.
Statistical analyses. Statistical analyses for comparison of two groups were conducted by an unpaired two-tailed t test. Distributed parameters were compared by one-way factorial analysis of variance. Significance was defined at P Ͻ 0.05 in both statistical analyses.
RESULTS
Adjuvant activity of MPL-SE and MPL-AF in humoral immunity. To determine the MPL dose required for enhancing the DNA-derived antigen-specific Ab response in a murine model, dose-related responses were analyzed by ELISA for both types of MPL. Mice were each immunized with 2 g of pCMV160IIIB/REV formulated with 0, 5, 20, 50, or 100 l of MPL-SE, and anti-PND IgG titers in serum were examined by ELISA. Doses of 20 to 100 l of both types of MPL significantly enhanced the antigen-specific Ab titer (Fig. 1) . No substantial differences between the Ab responses to MPL-SE and MPL-AF were observed. Negative control sera obtained from the mice injected with each type of MPL did not show a detectable Ab response. These results suggest that the dose of MPL sufficient for producing an enhanced Ab response is at least 50 l per mouse. The possibility remains that higher Ab titers are obtained when over 100 l of MPL is administered, and it was noted that the P value was smaller than 0.05 (comparison with control sera) when 20 l was used, but there were no significant differences in titer between antisera treated with VOL. 65, 1997 ADJUVANT EFFECT OF MPL IN DNA AIDS VACCINE 3521 50 l and those treated with 100 l of MPL. The 50-l dose was therefore used for further assays to evaluate HIV-1-specific functional humoral immunities and for CAT-related experiments. The concentration of p24 protein produced was assayed with the day 14 and day 28 antisera to determine whether they had an inhibitory effect on virus growth. The immune serum samples obtained with both formulations of MPL inhibited p24 protein production significantly more than those obtained without any adjuvants (Table 1) . When the MPL-AF formulation was used, a lower p24 concentration than the one obtained with MPL-SE was observed at both time points. However, no statistical difference between MPL-AF and MPL-SE for reducing p24 concentration was observed. An antifusion assay was carried out to determine whether these sera have an inhibitory effect on syncytium formation between infected and uninfected cells. When the adjuvants were added, augmented antifusion activity at the lower serum concentrations (dilutions) was observed, while antisera without adjuvant showed efficacy only at the higher serum concentrations. And statistical significance between the adjuvanted and nonadjuvanted groups at the 1:64 and 1:256 dilution points was noted ( Fig. 2) . Also in this assay, the two preparations of MPL showed similar adjuvant activities.
Adjuvant activities of MPL-SE and MPL-AF in CMI.
Doserelated CTL activities and DTH responses were also evaluated with 0, 5, 20, 50, and 100 l of both kinds of MPL, each formulated with 2 g of plasmid DNA. CTL activities were determined by a standard 51 Cr release assay 21 days after immunization. As Fig. 3 shows, strongly enhanced CTL activity was obtained not only at an E/T ratio of 80 but also at an E/T ratio of 20 by 50 and 100 l of both preparations of MPL. Effector cells from the mice injected with adjuvant alone did not show considerable cytolysis (data not shown). Augmentation of cytolytic activities against the non-peptide-pulsed target cells when 50 or 100 l of MPL was administered was also noted. This suggested activation of nonspecific cytolytic cells, FIG. 1. HIV-1 IIIB PND-specific Ab titers in antisera each immunized with 2 g of pCMV160IIIB and pcREV formulated with the indicated doses of MPL-SE or MPL-AF on 14 and 28 days after inoculation. Titers are represented as the reciprocal log 2 value, and the results for each group are the means Ϯ standard errors of the means for six mice. Statistical comparison between each adjuvanted and nonadjuvanted group was performed. * and **, significant differences defined at P Ͻ 0.05 and P Ͻ 0.01, respectively. Two separate experiments showed similar results. n.s., not significant.
FIG. 2.
Antifusion activities of antisera each immunized with 2 g of pCMV160IIIB and pcREV alone or formulated with 50 l of the indicated adjuvant 28 days after inoculation. The antifusion activities are expressed as percent reductions in the levels of syncytium formation compared with the levels obtained with the serum-free culture media and were obtained by titration with serial dilutions of the serum samples. The results of each group are the mean activities for four to six samples, determined by duplicated assay, and the error bars express standard errors of the means. *, statistical significance defined at P Ͻ 0.05. N.C., negative control (sera from naive mice). None (negative control) None 10.1 Ϯ 0. b Each value is the mean Ϯ standard error of the mean for three (negative control) or five (experimental group) mice. * and #, mean values significantly different from the value for the corresponding negative control (P Ͻ 0.01) and the value for the mice immunized with DNA alone (P Ͻ 0.05), respectively. such as NK cells, was also caused by valid adjuvanted vaccination; however, the main portion of enhanced specific cytolytic activity was supposed to be due to CD8ϩ lymphocytes. DTH responses were assayed by the footpad swelling test 14 days after immunization, and Table 2 shows that when over 20 l of MPL was formulated with the immunogen, the responses were significantly augmented and the maximal swelling response was elicited by 50 l of both kinds of MPL. No considerable differences between MPL-SE and MPL-AF in either antigenspecific CTL activity or antigen-specific DTH response were noted. These results indicated that 50 l of both types of MPL per mouse was sufficient to enhance antigen-specific CTL activity and DTH responses and therefore suggested that the adjuvant formulation had no effect on the adjuvant activities of the MPL preparations and that the enhancement of antigenspecific humoral and cell-mediated immune responses was based on the action of MPL itself.
Anti-DNA antibody responses. ELISA procedures for anti-DNA Abs were carried out to determine whether the MPL adjuvants augment anti-DNA Ab production. stDNA, plasmid pCMV160IIIB, and pcREV were each used as the antigen. Figure 4 shows that both preparations of MPL tended to weakly augment anti-DNA Abs production but not to a statis- tically significant extent. Positive control sera obtained from autoimmune mice yielded responses markedly stronger than those yielded by experimental samples for all DNA. No major differences were seen among the three kinds of DNA antigens in the generation of anti-DNA Abs for the experimental groups.
Antigen-specific immunoglobulin subclass analysis. The subclass of HIV-1-specific IgG was determined 28 days after immunization ( Table 3 ). The subclass patterns between the DNA and peptide vaccines were markedly different, as the table shows; that is, the IgG2a production by DNA vaccination was sufficiently detectable while that by the peptide vaccination without MPL was not detected, suggesting that the Th1-type response was dominant in genetic immunization. When MPL-SE or MPL-AF was formulated with the immunogen, the IgG1/IgG2a ratio tended to decrease in the DNA-vaccinated group, and the peptide group also showed detectable IgG2a production. The lowest IgG1/IgG2a ratio was obtained with the combination of DNA and MPL-SE: the IgG1 production decreased and the IgG2a production increased, causing a notable drop in the IgG1/IgG2a ratio, which was significantly lower than that obtained with DNA alone. MPL-AF also lowered the IgG1/IgG2a ratio in the DNA-vaccinated group, but this result was not statistically significant compared to that obtained without any adjuvant (P ϭ 0.06).
CAT expression in muscle and serum anti-CAT antibody responses. A CAT assay and ELISA for CAT Ab were performed to examine the mechanism of adjuvant action and to compare the efficacies of the methods of obtaining improved humoral immune responses from genetic immunization. In CAT ELISA, since 2 g of pCMV-CAT alone was not enough to produce a detectable level of CAT-specific IgG, we immunized 10 g of CAT DNA for precise comparison of nonadjuvanted and adjuvanted groups. As Fig. 5 shows, both types of MPL significantly reduced the level of muscular CAT expression in comparison with the level in the group that received no additional agents, but interestingly, they augmented anti-CAT Ab production. Also in this assay, adjuvant formulation did not affect the degree of CAT expression, suggesting that MPL itself reduced CAT activity in muscle. We wish to emphasize that, in ELISA, both MPL preparations enhanced not only HIV-1-specific Ab but also anti-CAT Ab. This finding is very important, because it implies that MPL may act as an effective adjuvant for various types of immunogenic DNA that encode other microbial antigenic proteins. BPVC enhanced both CAT expression and Ab production, but the degree of augmentation of Ab production by BPVC was less than that achieved by MPL.
Separate administration of the immunogenic DNA and adjuvant. To determine whether MPL acted on DNA itself or on in vivo-synthesized protein, adjuvant was injected 5 days following DNA inoculation. A 5-day interval was chosen because maximal expression of gene product (CAT) was observed 5 to 7 days after DNA injection in our preliminary experiments (data not shown) and similar results were reported elsewhere (34, 37) . Table 4 shows that the mean titers for the separateadministration groups were higher than those for the simultaneous-administration groups; however, the statistical differences between the corresponding groups were not determined. Also in the CTL assay, separate administration elicited cytolytic activity higher than that elicited by concurrent injection (Fig. 6 ), but statistical significance was not noted. Therefore we could not determine whether it was DNA or protein that was more efficiently affected by MPL under these conditions. On c Significantly different from the mean value for mice immunized with DNA alone (P Ͻ 0.01).
d NA, not available. e ND, not detected.
the other hand, both DNA and synthesized protein may be subjected to the immunomodulatory action of MPL.
Histopathological examination of the MPL-injected muscle.
A histopathological section of the muscle injected with DNA and MPL (Fig. 7A) showed massive accumulation of mononuclear cells, indicating that strong inflammation was caused by MPL injection. Furthermore, heterogeneous staining intensity and destructive changes of the muscle fibers associated with severe inflammatory-cell recruitment were noted; these findings suggested that degeneration and necrosis of the myocytes were mediated by these cells. In the muscle injected with DNA alone (Fig. 7B) , although similar findings were observed, the degrees of mononuclear-cell infiltration and muscle fiber change were distinguishably mild. These results may be able to explain the reduction of CAT expression in the muscle treated with MPL.
DISCUSSION
Techniques for enhancing immune responses by genetic immunization are of major interest in current vaccine study. We have provided the first evidence that MPL, an immunological adjuvant conventionally used in experimental peptide-based vaccines, has an adjuvant effect also on DNA vaccination. Our results demonstrate that two kinds of preparations of MPL have almost the same immunomodulatory effects on DNA vaccination against HIV-1. They enhanced all assayed parameters of both humoral and cell-mediated immunity: Ab titer (Fig. 1), antifusion activity (Fig. 2) , neutralizing activities (Table 1), DTH response (Table 2) , and CTL activity (Fig. 3) . Both preparations of MPL tended to little augment the anti-DNA Ab response (Fig. 4) . IgG subclass analysis (Table 3) revealed that both preparations of MPL produced predominantly IgG2a Ab but only MPL-SE changed the IgG1/IgG2a ratio with statistical significance compared to the control group. CAT expression in muscles treated with MPL was significantly lower than it was in muscles not treated with MPL, but in contrast, the anti-CAT Ab titer was significantly higher (Fig. 5) . Separate administration of the adjuvants and immunogenic DNA elicited both higher Ab titer and higher cytolytic activity than concurrent injection (Table 4 and Fig. 6 ), but statistical significance between the separate-and simultaneousadministration groups was not noted. Histopathological examination of the MPL-injected muscle revealed massive accumulation of inflammatory cells and segmental degeneration and necrosis of myocytes (Fig. 7) . These findings throw some important light on possible development strategies for effective DNA vaccines.
The first illuminating finding is that conventional immunologic adjuvants show effectiveness in genetic immunization, which suggests a new way to improve the potency of DNA vaccines. In previous studies designed to obtain immune responses by DNA vaccination, a number of approaches were attempted in order to enhance responses. One of these approaches is the gene gun delivery system, which has been used to improve the efficacy of plasmid DNA transfection (16, 27) . The potential advantage of this method is that APCs in the skin (dendritic cells), but not in skeletal muscles, may be transfected directly, and this transfection technique should reduce the amount of DNA required (11) . However, this advantage is counterbalanced by the requirement for gold beads and for a bombarding device connected to a large tank of pressurized gas to drive it. Although the development of this system is now on the way to refinement, at present, formulating immunolog- FIG. 6 . CTL activity of the bulk splenic mononuclear cells from the mice immunized with 2 g of pCMV160IIIB and pcREV. The indicated preparations of MPL were administered simultaneously as cocktails of immunogen and adjuvant (left panel) or separately 5 days following DNA injection (right panel). Other detailed conditions are the same as those specified in the legend for Fig. 3 . Activity of specific cytolysis was obtained by titration, with E/T ratios of 5, 20, and 80. Nonspecific cytolytic activity was measured at an E/T ratio of 80. The results are the means for two (negative control) or three (experimental group) mice and were determined by duplicated assay, and the error bars express standard errors of the means. No statistical differences between the simultaneous-and separate-administration groups adjuvanted with both MPL-SE and MPL-AF were detected at any titration points. NC, negative control (P815 target cells without peptide pulse). 6.4 Ϯ 0.9 NA a Mice were immunized with 2 g each of pCMV160IIIB and pcREV. The indicated preparations of MPL (50 l) were administered simultaneously as cocktails of immunogen and adjuvant or separately 5 days following DNA injection. The control group was immunized with immunogenic DNA alone.
b Data are presented as the means Ϯ standard errors of the means for five mice for each group. No statistical differences between the simultaneous-and separate-administration groups adjuvanted with both MPL-SE (P ϭ 0.07) and MPL-AF (P ϭ 0.10) were detected. NA, not available.
ical adjuvants with plasmid DNA is more simple and economical than using the gene gun system. This is an important consideration for large-scale vaccination protocols initiated in third-world countries endeavoring to combat a pandemic of AIDS. Another approach that has been attempted is to enhance immune response by improving gene transfer into skeletal muscle cells. BPVC, a lipophilic local anesthetic, is known to induce muscle necrosis at the injection site (1) . Previous studies (34, 37) have reported that muscle regeneration induced by BPVC significantly increases gene expression following plasmid injection 2 to 7 days after BPVC treatment. In this technique, administration of immunogenic DNA following BPVC injection must increase the expression of encoded protein in muscle cells and subsequently induce augmented immune responses (7) . We therefore compared MPLs and BPVC for their adjuvant activities; MPLs showed stronger activity for Ab production than BPVC (Fig. 5) .
A disadvantage of using MPL in DNA vaccination should also be pointed out: the tendency of MPL to augment anti-DNA Ab production (Fig. 4) . However, the amount of anti-DNA Ab induced was obviously lower than that found in autoimmune mice, and Mor et al. (18) demonstrated that DNA vaccines including the plasmid used in the present study do not induce autoimmune diseases despite a transient increase of anti-DNA antibody titer. Thus, we believe that the approach using MPL in DNA vaccination is effective, inexpensive, practical, and safe.
The second important finding is that increasing the amount of antigenic protein in muscle cells is not correlated with enhancement of the resultant Ab response (Fig. 5) . We wish to emphasize the fact that, despite the reduced CAT expression in muscle cells, anti-CAT Ab production is significantly augmented by MPL. These findings allow us to compose some hypotheses to explain this unexpected phenomenon: (i) muscle cells expressing foreign protein are subjected to the attack of recruited cells, including cytotoxic T cells, and this leads to release of the gene product from muscle; (ii) severe inflammatory changes at the injection site caused DNA and/or protein degradation; and (iii) lymphoid cells accumulated at the injection site are likelier to be transfected than myocytes (competition of DNA uptake between lymphoid cells and myocytes). In the study by Vilquin et al. (33) , a massive accumulation of lymphoid cells was observed surrounding the myocytes transfected with ␤-galactosidase, and granzyme B, a representative cytotoxin, was detected in the injected muscle. We should pay attention to the fact that these findings were correlated with a reduction in the intensity of muscular staining of ␤-galactosidase. Furthermore, they demonstrated that expression of the gene product was stronger and more prolonged in the muscle treated with an immunosuppressant (FK506) than in that of immunocompetent mice. Their results may be able to explain the reduction of CAT protein we observed and support the first hypothesis. Our histopathological examination shows myocyte necrosis (Fig. 7) and also supports the first hypothesis. However, the other hypotheses are also possible. In addition, it remains uncertain whether the adjuvant action of BPVC is mediated by the elevated expression of antigenic protein in regenerating muscle cells or via the uptake and expression of DNA by immune cells recruited to the site of tissue damage. Further studies to clarify these issues are awaited.
When immunogenic DNA and MPL were administered at intervals of 5 days, both the humoral and the cell-mediated immune responses seemed to be enhanced. Since that result was not statistically significant, determination of the mechanism of adjuvant action was impossible. We can only suppose that in vivo-synthesized protein is likelier than DNA itself to be FIG. 7 . Light photomicrograph of the bicep femoris muscle injected with a mixture of 10 g of pCMV-CAT and 50 l of MPL-SE (A) and with the same amount of pCMV-CAT alone (B). Magnification, ϫ100. Muscles were resected 3 days after injection, and the prepared sections were stained with hematoxylin and eosin. The muscle injected with the same DNA and 50 l of MPL-AF exhibited characteristics (data not shown) similar to those shown in photograph A. affected by MPL, and both may be subjected to the immunomodulatory action of MPL. The mode of DNA delivery and the mechanism of antigen presentation are controversial points in the study of genetic immunization (11, 14) . Ulmer et al. (30) have advocated three possible modes of antigen presentation: (i) antigen presentation by the muscle cells themselves, (ii) direct transfection of professional APCs, and (iii) transfer of antigen from transfected muscle cells to professional APCs. They have concluded that the third possibility offers the best explanation for their results. In the present study, the results of the CAT assay (Fig. 5 ) and the histopathological findings (Fig.  7) imply that antigenic protein is released from myocytes and support the opinion of Ulmer et al. Yet, the second possibility still remains.
The third finding is that the immunogenic DNA formulated with MPL elicits both enhanced humoral and cell-mediated immune responses. Although DNA vaccines without adjuvant are able to generate antigen-specific humoral and cellular immune responses, when pCMV160IIIB/REV immunogen was formulated with MPL, the functional Ab level, DTH response, and CTL activity were all consistently enhanced. Therefore, formulating immunogenic DNA with MPL is beneficial for augmenting the potency of DNA vaccinations. The use of MPL as an adjuvant for vaccines is based on the consequences of its activation of macrophages (3) and its ability to induce IFN-␥ and IL-2 (9, 32), as stated above. We conjecture that enhancement of some immunological parameter was caused by activation of the APCs through elicitation of these cytokines at the injection site, as Xiang and Ertl reported (38) . Furthermore, it is well known that both IFN-␥ and IL-2 are definitive cytokines secreted from Th1 lymphocytes (19) . Predominant activation of the Th1-derived immune system elicits a DTH response and IgG2a Ab production in mice (35) , and our results accommodate this. Of the murine immunoglobulins, IgG2a is considered to be the most effective subclass for inducing protective immunity against some pathogenic microbes (12, 36). We therefore suppose that enhancement of functional humoral immunity ( Fig. 2; Table 1 ) was based on elicitation of IgG2a by MPL.
In conclusion, strong adjuvant activity of MPL in the DNA vaccination against HIV-1 was confirmed by the present study. This is, to our knowledge, the first study in which a conventional immunological adjuvant yielded an adjuvant effect on genetic immunization. This new approach is simple and useful for enhancing an antigen-specific immune response, so that further attempts to evaluate in vivo protective potential against some virus challenges and another combination of immunogenic DNA and immunological adjuvant are eagerly awaited. And it is not the case that only pursuing enhancement of immunological responses is needed; investigating mechanistic aspects of DNA vaccination is also necessary.
